DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Schwab N et al.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Neurology 2013;
81: 865-871
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.